Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Lucentis

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Lucentis was produced by Novartis and Roche.

Promoting off-label use: where to draw the line?

Promoting off-label use: where to draw the line? Such an approach would also harm innovation. While the report often cites Lucentis and Avastin as examples of the perceived issue (with some remarks about the drugs' common origin), it does

Novartis' AMD drug pegpleranib fails phase III programme

Novartis' AMD drug pegpleranib fails phase III programme Plans for Lucentis-boosting duel-therapy stumble as trial data show no additional benefit. ... or wet forms of AMD provided no additional benefit over Lucentis given alone.

Lucentis claims speedy FDA review for myopia complication

Lucentis claims speedy FDA review for myopia complication The US FDA has said it will use its six-month review process for Roche's Lucentis as a treatment for choroidal neovascularization in patients with severe near-sightedness (myopia). ... If approved, Lucentis could be an important tool in helping these

NICE backs Bayer’s Eylea as first-line BRVO treatment

NICE backs Bayer’s Eylea as first-line BRVO treatment Recommends visual impairment therapy over current laser treatment

Dr Robert Kim joins Apellis as chief medical officer

Dr Robert Kim joins Apellis as chief medical officer While at Genentech he managed the Lucentis phase III clinical programme through to its first approval in wet age related macular degeneration.

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Real Science Communications

Real Science Communications is a scientific centre of excellence, infusing credibility and scientific rigour into the conversations around health and...

Latest intelligence

Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....

Infographics